E-Therapeutics enters deal with a top-five pharmaceutical company
Francesca Morgan
Company News - 2 mins
11:06, 13th August 2019

Oxford-based E-therapeutics (ETX) FOLLOW announced on Tuesday that it had agreed to work with a global, “top five” pharmaceutical company on a drug discovery project associated with neurodegenerative diseases.

The project, taken on by e-therapeutics and the unnamed drug firm, will focus on the specific area of biology related to neurodegenerative diseases, a condition which affects over one billion people across the globe currently. 

Dr Ray Barlow, CEO at E-Therapeutics, said: "We are thrilled to be working with one of the largest global pharma companies in an exciting area of disease biology where there is a significant unmet need.”

Shares in E-therapeutics were up over 16% this morning following the news. 

The ambitions of E-therapeutics revolve around revolutionising disease treatment by offering a new reductionist approach to drug discovery. 

And now the company are aiming to delve into effective research for Neurodegenerative disease -- the disease occurs when there is progressive loss of structure or function of neurons, which can lead to a range of diseases such as Parkinson’s, Alxeimer’s and Huntington’s. 

As an area that has seen little innovation until recently, drug discovery is considered unsustainable with huge room for improvement -- advancement here will be particularly significant in treating diseases, specifically those that are so widespread.

Up until now, traditional approaches have also seen pharmaceutical companies take the hit with declining investment returns due to high failure rates.

Dr Barlow commented, “This deal will allow us to directly showcase our Network-Driven Drug Discovery (NDD) technologies to them and the work has the potential to generate new therapeutic assets to add to our existing portfolio.”

Under the 12-month agreement, the AIM-listed company will use the NDD approach to identify novel disease pathways.

The results and the IP of the project will remain the property of E-Therapeutics.

Dr Barlow further added: “We continue to work on a number of different types of external collaborations and look forward to sharing further news during the remainder of the year."

For more News & Updates on E-Therapeutics: FOLLOW

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Login or register to post comments

Recent Articles